Advertisement

T-Cell Adoptive Immunotherapy

  • Gregory E. Plautz
  • Peter A. Cohen
  • David E. Weng
  • Suyu Shu
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Adoptive transfer originally referred to the ability to confer protective immunity on a naïve host via infusion of T lymphocytes from an immune donor. This term now also encompasses a strategy of cancer therapy in which autologous T cells are acquired from a tumor-bearing host then activated and numerically expanded ex vivo prior to reinfusion. It has been nearly 50 yr since Mitchison’ s initial observation that adoptive transfer of “cellular elements” from immune hosts could accelerate rejection of tumor transplants in naïve recipients (1). Since then, considerable progress has been made in defining T lymphocytes as the central component of the antitumor response with the ability to directly kill tumor cells and orchestrate other host effector mechanisms. With the importance of T cells firmly established, tumor-reactive T-cell clones have been successfully used as probes to identify tumor-associated antigens that are currently being investigated as vaccine reagents.

Keywords

Renal Cell Carcinoma Adoptive Transfer Metastatic Renal Cell Carcinoma Adoptive Immunotherapy General Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J Exp Med 1955; 102:157–177.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380–384.PubMedCrossRefGoogle Scholar
  3. 3.
    Billingham RE, Brent L, Medawar PW. Quantitative studies on tissue transplantation immunity II: the origin, strength and duration of actively and adoptively acquired immunity. Proc Roy Soc Biol 1954; 143:58–80.PubMedCrossRefGoogle Scholar
  4. 4.
    Klein G, Sjogren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthreneinduced sarcomas in the primary autochthonous host. Cancer Res 1960; 20:1561–1572.PubMedGoogle Scholar
  5. 5.
    Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18:769–778.PubMedGoogle Scholar
  6. 6.
    Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 1976; 33:241.PubMedCrossRefGoogle Scholar
  7. 7.
    Borberg H, Oettgen HF, Chondry F, Beattie EJ, Jr. Inhibition of established transplants of chemically induced sarcomas in syngenic mice by lymphocytes from immunized donors. Int J Cancer 1972; 10: 539–547.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith HG, Harmel RP, Hanna MG, Jr., Zwillig BS, Zbar B, Rapp HJ. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. J Natl Cancer Inst 1977: 58:1315–1322.PubMedGoogle Scholar
  9. 9.
    Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 25:323–388.PubMedCrossRefGoogle Scholar
  10. 10.
    Cheever MA, Greenberg PD, Fefer A. Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and non-specifically expanded by culture with interleukin 2. J Immunol 1981; 126:1318–1322.PubMedGoogle Scholar
  11. 11.
    Eberlein T, Rosenstein JM, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. J Exp Med 1982; 156:385–397.PubMedCrossRefGoogle Scholar
  12. 12.
    Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159:495–507.PubMedCrossRefGoogle Scholar
  13. 13.
    Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318–1321.PubMedCrossRefGoogle Scholar
  14. 14.
    Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 1987; 139:295–304.PubMedGoogle Scholar
  15. 15.
    Shu S, Chou T, Rosenberg SA. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Research 1987; 47:1354–1360.PubMedGoogle Scholar
  16. 16.
    Liu J, Finke J, Krauss JC, Shu S, Plautz GE. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules. Cancer Immunol Immunother 1998; 46:268–276.PubMedCrossRefGoogle Scholar
  17. 17.
    Uzzo RG, Clark PE, Rayman P, Bloom T, Rybicki L, Novick AC, et al. Alterations in NFkB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 1999; 91:718–721.PubMedCrossRefGoogle Scholar
  18. 18.
    Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999; 48:346–352.PubMedCrossRefGoogle Scholar
  19. 19.
    Lockhart DC, Chan AK, Mak S, Joo HG, Daust HA, Carritte A, et al. Loss of T-cell receptor-CD3zeta and T-cell function in tumor- infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 2001; 129:749–756.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677–685.PubMedCrossRefGoogle Scholar
  21. 21.
    Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147:729–737.PubMedGoogle Scholar
  22. 22.
    Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991; 146:4414–4420.PubMedGoogle Scholar
  23. 23.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, et al. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 1994; 152:1277–1288.PubMedGoogle Scholar
  24. 24.
    Chin CS, Graham LJ, Hamad GG, George KR, Bear HD. Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J Surg Res 2001; 98:108–115.PubMedCrossRefGoogle Scholar
  25. 25.
    Anderson PM, Blazar BR, Bach FH, Ochoa AC. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity. J Immunol 1989; 142:1383–1394.PubMedGoogle Scholar
  26. 26.
    Yun YS, Hargrove ME, Ting CC. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49:4770–4774.PubMedGoogle Scholar
  27. 27.
    Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987; 79:1067–1075.PubMedGoogle Scholar
  28. 28.
    Yang JC, Perry-Lalley D, Rosenberg SA. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Mod 1990; 9:149–159.PubMedGoogle Scholar
  29. 29.
    McHeyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. Science 1995; 268:106–111.PubMedCrossRefGoogle Scholar
  30. 30.
    Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 1996; 56:4338–4342.PubMedGoogle Scholar
  31. 31.
    Tanigawa K, Takeshita N, Craig RA, Phillips K, Knibbs RN, Chang AE, et al. Tumor-specific responses in lymph nodes draining murine sarcomas are concentrated in cells expressing P-selectin binding sites. J Immunol 2001; 167:3089–3098.PubMedGoogle Scholar
  32. 32.
    Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001; 182:58–67.PubMedCrossRefGoogle Scholar
  33. 33.
    Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002; 25:207–217.PubMedCrossRefGoogle Scholar
  34. 34.
    Sondak VK, Wagner PD, Shu S, Chang AE. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg 1991; 126:442–446.PubMedCrossRefGoogle Scholar
  35. 35.
    Becker C, Pohla H, Frankenberger B, Schuler T, Assenmacher M, Schendel DJ, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7:1159–1162.PubMedCrossRefGoogle Scholar
  36. 36.
    Wahl WL, Sussman JJ, Shu S, Chang AE. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J Immunother 1994; 15:242–250.CrossRefGoogle Scholar
  37. 37.
    Peng L, Shu S, Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cellular Immunol 1997: 178:24–32.CrossRefGoogle Scholar
  38. 38.
    Inoue M, Plautz GE, Shu S. Treatment of intracranial tumors by systemic transfer of superantigenactivated tumor-draining lymph node T cells. Cancer Res 1996; 56:4702–4708.PubMedGoogle Scholar
  39. 39.
    Kjaergaard J, Shu S. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol 1999; 163:751–759.PubMedGoogle Scholar
  40. 40.
    Mukai S, Kjaergaard J, Shu S, Plautz GE. Infiltration of tumors by systemically transferred tumorreactive T lymphocytes is required for antitumor efficacy. Cancer Res 1999; 59:5245–5249.PubMedGoogle Scholar
  41. 41.
    Sussman JJ, Wahl WL, Chang AE, Shu S. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J Immunother 1995; 18:35–44.CrossRefGoogle Scholar
  42. 42.
    Kjaergaard J, Peng L, Cohen PA, Drazba JA, Weinberg AD, Shu S. Augmentation vs inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001; 167:6669–6677.PubMedGoogle Scholar
  43. 43.
    Dillman RO, Hurwitz SR, Schiltz PM, Barth NM, Beutel LD, Nayak SK, et al. Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer. Cancer Biother Radiopharm 1997; 12:65–71.PubMedCrossRefGoogle Scholar
  44. 44.
    Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111indiumlabeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994; 73:1731–1737.PubMedCrossRefGoogle Scholar
  45. 45.
    Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J, et al. Histopathologic analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumorinfiltrating lymphocytes. Cancer Immunol Immunother 1994; 38:299–303.PubMedCrossRefGoogle Scholar
  46. 46.
    Kagamu H, Shu S. Purification of L-selectinlow cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998; 160:3444–3452.PubMedGoogle Scholar
  47. 47.
    Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA. Helper-independent, L selectinlow CD8+ T cells with broad antitumor efficacy are naturally sensitized during tumor progression. J Immunol 2000; 165:5738–5749.PubMedGoogle Scholar
  48. 48.
    Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000; 20:17–56.PubMedCrossRefGoogle Scholar
  49. 49.
    Plautz GE, Mukai S, Cohen PA, Shu S. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 2000; 165:3656–3662.PubMedGoogle Scholar
  50. 50.
    Cohen PA, Peng L, Kjaergaard J, Plautz GE, Finke JH, Koski GK, et al. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 2001; 21:215–248.PubMedGoogle Scholar
  51. 51.
    Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 2000; 165:7116–7124.PubMedGoogle Scholar
  52. 52.
    Winter H, Hu HM, McClain K, Urba WJ, Fox BA. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity vs adoptive immunotherapy. J Immunol 2001; 166:7370–7380.PubMedGoogle Scholar
  53. 53.
    Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. J Natl Cancer Inst 1985; 75:67–75.PubMedGoogle Scholar
  54. 54.
    Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer 1985; 55:1327–1333.PubMedCrossRefGoogle Scholar
  55. 55.
    Yang JC, Mule JJ, Rosenberg SA. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells. J Immunol 1986; 137:715–722.PubMedGoogle Scholar
  56. 56.
    Roberts K, Lotze MT, Rosenberg SA. Separation and functional studies of the human lymphokineactivated killer cell. Cancer Res 1987; 47:4366–4371.PubMedGoogle Scholar
  57. 57.
    Mule JJ, Yang J, Shu S, Rosenberg SA. The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 1986; 136:3899–3909.PubMedGoogle Scholar
  58. 58.
    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin2 to patients with metastatic cancer. N Engl J Med 1985; 313(23):1485–1492.PubMedCrossRefGoogle Scholar
  59. 59.
    Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7:477–485.PubMedGoogle Scholar
  60. 60.
    Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, Sznol M, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 1991; 9:641–648.PubMedGoogle Scholar
  61. 61.
    Margolin KA, Rayner AA, Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 1989; 7:486–498.PubMedGoogle Scholar
  62. 62.
    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 1989; 25:S21–528.Google Scholar
  63. 63.
    Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85:622–632.PubMedCrossRefGoogle Scholar
  64. 64.
    Jacobs SK, Wilson DJ, Komblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 1986; 64:743–749.PubMedCrossRefGoogle Scholar
  65. 65.
    Yoshida S, Tanaka R, Takai N, Ono K. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 1988; 48:5011–5016.PubMedGoogle Scholar
  66. 66.
    Merchant RE, Merchant LH, Cook SHS, McVicar DW, Young HF. Intralesional infusion of lymphokine-activated killer cells and recombinant interleukin-2 for the treatment of patients with malignant brain tumor. Neurosurgery 1988; 23:725–732.PubMedCrossRefGoogle Scholar
  67. 67.
    Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 1995; 76:840–852.PubMedCrossRefGoogle Scholar
  68. 68.
    Hayes RL, Arbit E, Odaimi M, Pannullo S, Scheff R, Kravchinskiy D, et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 2001; 39:31–42.PubMedCrossRefGoogle Scholar
  69. 69.
    Kruse CA, Schiltz PM, Bellgrau D, Kong Q, Kleinschmidt-De Masters BK. Intracranial administrations of single of multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol 1994; 19:161–168.PubMedCrossRefGoogle Scholar
  70. 70.
    Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 1997; 45:77–87.PubMedCrossRefGoogle Scholar
  71. 71.
    Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10:535–544.PubMedCrossRefGoogle Scholar
  72. 72.
    Graham S, Babayan RK, Lamm DL, Sawczuk I, Ross SD, Lavin PT, et al. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Semin Urol 1993; 11:27–34.PubMedGoogle Scholar
  73. 73.
    Lavin PT, Maar R, Franklin M, Ross S, Martin J, Osband ME. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice. Transplant Proc 1992; 24:3059–3064.PubMedGoogle Scholar
  74. 74.
    Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer 1995; 31A:698–708.CrossRefGoogle Scholar
  75. 75.
    Garlie NK, Siebenlist RE, LeFever AV. T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations. J Urol 2001; 166:299–303.PubMedCrossRefGoogle Scholar
  76. 76.
    Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor vs costimulatory signals. J Immunology 1996; 157:3280–3289.Google Scholar
  77. 77.
    Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP, Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial. J Immunother 2001; 24:408–419.CrossRefGoogle Scholar
  78. 78.
    Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163:6292–6300.PubMedGoogle Scholar
  79. 79.
    Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, et al. Induction of primary NY-ES0–1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO1+ cancers. Proc Natl Acad Sci U S A 2000; 97:12198–12203.PubMedCrossRefGoogle Scholar
  80. 80.
    Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477–484.PubMedCrossRefGoogle Scholar
  81. 81.
    Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8:631–637.PubMedCrossRefGoogle Scholar
  82. 82.
    Barth RJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon g and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173:647–658.PubMedCrossRefGoogle Scholar
  83. 83.
    Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int J Cancer 1996; 65:413–421.PubMedCrossRefGoogle Scholar
  84. 84.
    Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159–1166.PubMedCrossRefGoogle Scholar
  85. 85.
    Schwartzentruber DJ, Hom SS, Dadmarz R, White DE, Yannelli JR, Steinberg SM, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol 1994; 12:1475–1483.PubMedGoogle Scholar
  86. 86.
    Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 2000; 23:17–27.PubMedCrossRefGoogle Scholar
  87. 87.
    Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24:363–373.PubMedCrossRefGoogle Scholar
  88. 88.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850–854.PubMedCrossRefGoogle Scholar
  89. 89.
    Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 1991; 51:4199.PubMedGoogle Scholar
  90. 90.
    Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Research 1993; 53:1380–1387.PubMedGoogle Scholar
  91. 91.
    Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, et al. Loss of T-cell receptor z chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993; 53:5613–5616.PubMedGoogle Scholar
  92. 92.
    Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldwater N, Gitlitz B, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8 (+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997; 158:740–745.PubMedCrossRefGoogle Scholar
  93. 93.
    Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999; 17:2521–2529.PubMedGoogle Scholar
  94. 94.
    Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Leveque J, Guille F, et al. Interleukin2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytokine Netw 2000; 11:217–224.PubMedGoogle Scholar
  95. 95.
    Mulder WM, Stukart MJ, Roos M, van Lier RA, Wagstaff J, Scheper RJ, et al. Culture of tumourinfiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity. Cancer Immunol Immunother 1995; 41:293–301.PubMedCrossRefGoogle Scholar
  96. 96.
    Crannage KE, Rogers K, Jacob G, Stoddard CJ, Thomas WE, Potter CW, et al. Factors influencing the establishment of tumour-infiltrating lymphocyte cultures from human breast carcinoma and colon carcinoma tissue. Eur J Cancer 1991; 27:149–154.PubMedCrossRefGoogle Scholar
  97. 97.
    Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside TL. Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 1990; 98:259–268.PubMedGoogle Scholar
  98. 98.
    Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98:14565–14570.PubMedCrossRefGoogle Scholar
  99. 99.
    Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 1999; 45:141–157.PubMedCrossRefGoogle Scholar
  100. 100.
    Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15:796–807.PubMedGoogle Scholar
  101. 101.
    Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997; 178:101–107.PubMedCrossRefGoogle Scholar
  102. 102.
    Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998; 89:42–51.PubMedCrossRefGoogle Scholar
  103. 103.
    Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000; 6:2209–2218.PubMedGoogle Scholar
  104. 104.
    Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE, et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 1999; 54:617–623.PubMedCrossRefGoogle Scholar
  105. 105.
    To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, et al. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 2000; 126:1225–1231.PubMedGoogle Scholar
  106. 106.
    Peng L, Kjaergaard J, Plautz GE, Awad M, Drazba J, Shu S, Cohen PA. Tumor-induced L-seledinhigh suppressor T cells can mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002; 169:4811–4821.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Gregory E. Plautz
  • Peter A. Cohen
  • David E. Weng
  • Suyu Shu

There are no affiliations available

Personalised recommendations